Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Entasis Therapeutics Holdings (NASDAQ: ETTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company will host a fireside chat available on-demand starting September 13 at 7:00 AM ET, alongside one-on-one investor meetings. Entasis focuses on developing novel antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, featuring a robust pipeline, including treatments for Acinetobacter baumannii and Neisseria gonorrhoeae.

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23^rd Annual Global Investment Conference. Details of the Company’s participation are as follows:

Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Dates: September 13-15, 2021
Format:	Fireside chat available on-demand beginning September 13th at 7:00am ET
	One-on-one investor meetings

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts         
Company:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com

FAQ

When will Entasis Therapeutics participate in the H.C. Wainwright conference?

Entasis Therapeutics will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What is the format of Entasis Therapeutics' presentation at the conference?

Entasis Therapeutics will host a fireside chat available on-demand starting September 13 at 7:00 AM ET, along with one-on-one investor meetings.

What does Entasis Therapeutics focus on?

Entasis Therapeutics specializes in the discovery and development of novel antibacterial products for serious infections caused by multidrug-resistant bacteria.

What are some product candidates in Entasis Therapeutics' pipeline?

Entasis Therapeutics' pipeline includes sulbactam-durlobactam for Acinetobacter baumannii infections and zoliflodacin for Neisseria gonorrhoeae infections.